- Home
- CRGX vs PCRX Comparison
CRGX vs PCRX Comparison
Compare CRGX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- PCRX
- Stock Information
- Founded
- CRGX 2021
- PCRX 2006
- Country
- CRGX United States
- PCRX United States
- Employees
- CRGX N/A
- PCRX N/A
- Industry
- CRGX
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- PCRX Health Care
- Exchange
- CRGX Nasdaq
- PCRX Nasdaq
- Market Cap
- CRGX 621.4M
- PCRX 604.7M
- IPO Year
- CRGX 2023
- PCRX 2011
- Fundamental
- Price
- CRGX $13.46
- PCRX $24.52
- Analyst Decision
- CRGX Strong Buy
- PCRX Buy
- Analyst Count
- CRGX 6
- PCRX 10
- Target Price
- CRGX $31.80
- PCRX $27.60
- AVG Volume (30 Days)
- CRGX 231.3K
- PCRX 741.3K
- Earning Date
- CRGX 03-20-2025
- PCRX 02-27-2025
- Dividend Yield
- CRGX N/A
- PCRX N/A
- EPS Growth
- CRGX N/A
- PCRX N/A
- EPS
- CRGX N/A
- PCRX N/A
- Revenue
- CRGX N/A
- PCRX $694,957,000.00
- Revenue This Year
- CRGX N/A
- PCRX $4.83
- Revenue Next Year
- CRGX N/A
- PCRX $2.16
- P/E Ratio
- CRGX N/A
- PCRX N/A
- Revenue Growth
- CRGX N/A
- PCRX 4.40
- 52 Week Low
- CRGX $10.91
- PCRX $11.16
- 52 Week High
- CRGX $33.92
- PCRX $34.01
- Technical
- Relative Strength Index (RSI)
- CRGX 47.00
- PCRX 76.79
- Support Level
- CRGX $12.51
- PCRX $18.18
- Resistance Level
- CRGX $15.75
- PCRX $22.36
- Average True Range (ATR)
- CRGX 1.09
- PCRX 1.28
- MACD
- CRGX 0.17
- PCRX 0.39
- Stochastic Oscillator
- CRGX 52.74
- PCRX 89.19
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.